[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intensive-care-unit-survivors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intensive-care-unit-survivors":51},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100615649",false,"NCT07295353","Accelerating Recovery After ICU Admission: Post-discharge Supplementation With Pasteurized Akkermansia Muciniphila.","PAM-ICU","Inclusion Criteria:\n\n* Age ≥18 years\n* Treated in the ICU for at least 2 days and discharged to a regular clinical ward\n* Diagnosed with sepsis during ICU admission\n* Received selective digestive decontamination (SDD) or cephalosporin\n* Capable of giving written informed consent\n\nExclusion Criteria:\n\n* Recent major gastrointestinal surgery\n* Diagnosed with ulcerative colitis or Crohn's disease\n* Presence of a hematological malignancy and\u002For current use of immunomodulatory therapy (e.g., CAR-T cell therapy or immune checkpoint inhibitors) Use of systemic immunomodulatory drugs or corticosteroids (defined as ≥10 mg prednisone equivalent daily at ICU discharge), at the time of inclusion.\n* History of solid organ or stem cell transplantation\n* Pregnancy or lactation\n* Donation of blood or plasma within 30 days prior to inclusion or planned donation during the intervention period\n* Any other condition that, in the opinion of the investigator, could pose a risk to the subject or interfere with study result","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this clinical trial is to learn if daily oral supplementation with pasteurized Akkermansia muciniphila (PAM), an EFSA-approved food supplement, can support recovery in adults who have recently been treated in the ICU for sepsis.\n\nThe main questions it aims to answer are:\n\n* Is PAM safe to take for 56 days after ICU discharge?\n* Does PAM increase the abundance of beneficial butyrate-producing bacteria in the gut?\n\nResearchers will compare PAM to a placebo (a capsule that looks the same but has no active ingredient) to see if PAM improves gut microbiota and immune recovery.\n\nParticipants will:\n\n* Take PAM or placebo capsules once daily for 56 days\n* Provide stool and blood samples at baseline, day 28, and day 56\n* Receive a follow-up phone call about their health 1 year after starting the study",[25,26,27,28,29],"Sepsis","Post Intensive Care Unit Syndrome","Critical Illness","Microbiome Dysbiosis","Intensive Care Unit Survivors",[31,32,33,34,35,36,37,38],"Pasteurized Akkermansia muciniphila","Akkermansia muciniphila","Postbioticum","Microbiome","PAM","Gut Barrier Function","Post-Sepsis Recovery","Randomized Controlled Trial","NOT_YET_RECRUITING","2025-12-08",{"date":42,"type":43},"2025-12-19","ACTUAL",{"date":45,"type":19},"2026-01",{"date":47,"type":19},"2028-01",{"name":49,"class":50},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",""]